ENIMMUNE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.55 TWD | +0.14% |
|
-5.08% | -7.87% |
| 03-13 | Enimmune corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Enimmune corporation Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,020 | 1,050 | 2,682 | 2,367 | 4,020 |
| Enterprise Value (EV) 1 | 793.6 | 884 | 2,268 | 2,025 | 3,563 |
| P/E ratio | -10.5 x | -18.5 x | -31.9 x | -49.9 x | -15.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 880 x | 540 x | 117 x | 21.6 x | 21.3 x |
| EV / Revenue | 685 x | 455 x | 99.2 x | 18.4 x | 18.9 x |
| EV / EBITDA | -7.99 x | -13.4 x | -29.9 x | -40.4 x | -12.8 x |
| EV / FCF | -15.8 x | -18.3 x | -25.2 x | -32.7 x | -27.9 x |
| FCF Yield | -6.33% | -5.45% | -3.96% | -3.06% | -3.59% |
| Price to Book | 2.87 x | 3.24 x | 4.34 x | 4.15 x | 7.38 x |
| Nbr of stocks (in thousands) | 40,000 | 44,000 | 60,000 | 60,000 | 65,800 |
| Reference price 2 | 25.51 | 23.86 | 44.70 | 39.45 | 61.10 |
| Announcement Date | 19-04-17 | 20-04-22 | 21-04-20 | 22-04-26 | 23-04-21 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.7 | 1.159 | 1.944 | 22.88 | 109.8 | 188.4 |
| EBITDA 1 | -34.14 | -99.35 | -65.98 | -75.77 | -50.18 | -278.2 |
| EBIT 1 | -37.61 | -104.3 | -71.87 | -82.72 | -58.67 | -286.4 |
| Operating Margin | -2,212.29% | -8,999.31% | -3,696.81% | -361.61% | -53.42% | -152.01% |
| Earnings before Tax (EBT) 1 | -34.28 | -100.8 | -56.64 | -74.45 | -47.25 | -267.1 |
| Net income 1 | -34.28 | -100.8 | -56.64 | -74.45 | -47.25 | -248 |
| Net margin | -2,016.18% | -8,696.03% | -2,913.84% | -325.46% | -43.02% | -131.6% |
| EPS 2 | -0.8569 | -2.438 | -1.287 | -1.400 | -0.7900 | -3.882 |
| Free Cash Flow 1 | -85.9 | -50.25 | -48.2 | -89.84 | -61.94 | -127.9 |
| FCF margin | -5,053.21% | -4,336.04% | -2,479.51% | -392.71% | -56.4% | -67.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 18-06-15 | 19-04-17 | 20-04-22 | 21-04-20 | 22-04-26 | 23-04-21 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 237 | 227 | 166 | 414 | 342 | 457 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -85.9 | -50.3 | -48.2 | -89.8 | -61.9 | -128 |
| ROE (net income / shareholders' equity) | -8.08% | -25.6% | -16.1% | -15.8% | -7.96% | -43.2% |
| ROA (Net income/ Total Assets) | -5.44% | -16.2% | -12.6% | -10.5% | -5.79% | -25.8% |
| Assets 1 | 630 | 622.8 | 451.2 | 710.7 | 816.7 | 959.4 |
| Book Value Per Share 2 | 10.20 | 8.880 | 7.360 | 10.30 | 9.500 | 8.280 |
| Cash Flow per Share 2 | 5.930 | 5.230 | 2.780 | 1.730 | 1.970 | 5.990 |
| Capex | - | - | - | 4.19 | 2.98 | 0.35 |
| Capex / Sales | - | - | - | 18.32% | 2.71% | 0.18% |
| Announcement Date | 18-06-15 | 19-04-17 | 20-04-22 | 21-04-20 | 22-04-26 | 23-04-21 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -7.87% | 70.01M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- 6564 Stock
- Financials Enimmune corporation